Abstract
Alzheimer’s disease (AD) is an irreversible neurodegenerative disorder responsible for most age-associated dementias, causing memory loss and cognitive impairment. In the absence of an effective cure, the current AD treatments are mainly focused on symptom management, with most FDA-approved drugs for AD acting as acetylcholinesterase (AChE) inhibitors. Diketopyrrolopyrroles (DPPs) are a class of planar N-containing heterocycles widely explored as high-performance dyes and pigments. However, their biological potential remains largely underexplored, with applications mainly limited to photodynamic therapy (PDT), photodynamic inactivation (PDI) and fluorescent DNA biosensing. To the best of our knowledge, the present study is the first to describe the design, synthesis and evaluation of a series of eleven DPPs for their inhibitory activity against both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The results demonstrate that the DPP scaffold is a promising core for the development of novel AChE and BuChE inhibitors, yielding several submicromolar inhibitors of both enzymes. Among them, derivative 14 emerged as the most active DPP against both AChE (IC50 0.13 ± 0.03 µM) and BuChE (IC50 0.21 ± 0.02 µM). Molecular docking studies further corroborated the experimental results, supporting a dual-site binding mode for the most active derivatives, involving both the catalytic active site (CAS) and peripheral anionic site (PAS). Although preliminary physicochemical and ADMET evaluation highlights the need for further optimization, this work establishes DPPs as a novel scaffold for the development of dual and selective cholinesterase inhibitors and provides a foundation for future anti-AD drug discovery.